A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma

Trial Profile

A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs HDM 201 (Primary) ; Ribociclib (Primary)
  • Indications Liposarcoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Mar 2017 Planned number of patients changed from 84 to 107.
    • 01 Mar 2017 Planned End Date changed from 1 Mar 2018 to 29 Dec 2018.
    • 01 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 29 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top